trending Market Intelligence /marketintelligence/en/news-insights/trending/iH43jG4_nds5Cwv9SeNk7Q2 content esgSubNav
In This List

NeuroVive raises 28.2M Swedish kronor in direct issue of shares

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


NeuroVive raises 28.2M Swedish kronor in direct issue of shares

NeuroVive Pharmaceutical AB raised 28.2 million Swedish kronor in gross proceeds from a directed new issuance of 20,897,854 shares.

Each share in the issue was priced at 1.35 Swedish kronor, a 5.1% discount to the closing price of NeuroVive's share listed on the Nasdaq Stockholm on March 6.

Proceeds from the issuance will be used to advance drug development activities.

Stockholm Corporate Finance was the financial adviser and sole book runner for the issue.

As of March 13, US$1 was equivalent to 9.31 Swedish kronor.